Thursday, May 3, 2012
AMAG Pharmaceuticals Inc., of Lexington, Mass., reported first-quarter revenues of $15.5 million, including $13.6 million in net revenues from Feraheme (ferumoxytol) injection in iron deficiency anemia (IDA). Net Feraheme product revenues for the first quarter were $13.6 million, compared to $10.9 million in the first quarter of 2011. Provider demand for the intravenous drug during the first quarter was approximately 26,600 grams, representing a 30 percent increase over the first quarter of 2011 and a 10 percent increase over the fourth quarter of 2011.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.